JPS6032714A - 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 - Google Patents
鼻腔粘膜に適用するための安定化された粉末状薬学的組成物Info
- Publication number
- JPS6032714A JPS6032714A JP58139466A JP13946683A JPS6032714A JP S6032714 A JPS6032714 A JP S6032714A JP 58139466 A JP58139466 A JP 58139466A JP 13946683 A JP13946683 A JP 13946683A JP S6032714 A JPS6032714 A JP S6032714A
- Authority
- JP
- Japan
- Prior art keywords
- application
- lower alkyl
- powder
- pharmaceutical composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 16
- 210000004400 mucous membrane Anatomy 0.000 title abstract description 4
- 229920002678 cellulose Polymers 0.000 claims abstract description 23
- 239000001913 cellulose Substances 0.000 claims abstract description 23
- 150000007524 organic acids Chemical class 0.000 claims abstract description 18
- 150000005215 alkyl ethers Chemical class 0.000 claims abstract description 16
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 11
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 11
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008117 stearic acid Substances 0.000 claims abstract description 11
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000009965 odorless effect Effects 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 13
- 210000002850 nasal mucosa Anatomy 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 6
- 229940092705 beclomethasone Drugs 0.000 claims description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 18
- 239000002245 particle Substances 0.000 abstract description 13
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract description 3
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract description 3
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 2
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 2
- 208000001319 vasomotor rhinitis Diseases 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- -1 β-carboxyethyl Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000005011 alkyl ether group Chemical group 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000020046 sherry Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100518359 Homo sapiens RHO gene Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000135194 Pione Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002858 crystal cell Anatomy 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58139466A JPS6032714A (ja) | 1983-08-01 | 1983-08-01 | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
| EP19850300205 EP0187433B1 (en) | 1983-08-01 | 1985-01-11 | Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity |
| US07/153,527 US4835142A (en) | 1983-08-01 | 1988-02-04 | Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58139466A JPS6032714A (ja) | 1983-08-01 | 1983-08-01 | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6032714A true JPS6032714A (ja) | 1985-02-19 |
| JPH0251528B2 JPH0251528B2 (enExample) | 1990-11-07 |
Family
ID=15245886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58139466A Granted JPS6032714A (ja) | 1983-08-01 | 1983-08-01 | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4835142A (enExample) |
| JP (1) | JPS6032714A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522997A (ja) * | 2004-12-09 | 2008-07-03 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 酸によるグルココルチコイドエステルの安定化 |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112804A (en) * | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
| IT8920486A0 (it) * | 1989-05-12 | 1989-05-12 | Isf Spa | Composizioni farmaceutiche. |
| US5776493A (en) * | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
| NL9002008A (nl) | 1990-09-12 | 1992-04-01 | Stichting Centr Diergeneeskund | Recombinant dna en rna en daarvan afgeleide produkten. |
| US5248310A (en) * | 1992-03-27 | 1993-09-28 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5512299A (en) * | 1992-03-30 | 1996-04-30 | Alza Corporation | Method of treating oral inflammatory disease |
| US5573776A (en) * | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| JPH07140076A (ja) * | 1993-11-12 | 1995-06-02 | Bio Sensor Kenkyusho:Kk | 粉体酸化剤組成物 |
| US5879712A (en) | 1995-06-07 | 1999-03-09 | Sri International | Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced |
| AU722319B2 (en) | 1996-02-27 | 2000-07-27 | Teijin Limited | Powdery composition for nasal administration |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| US20010053775A1 (en) * | 1998-01-30 | 2001-12-20 | Matthias Seidel | Nasal solutions |
| JPH11246439A (ja) * | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | 経粘膜用吸収促進剤 |
| DE69910183T2 (de) * | 1998-03-11 | 2004-06-03 | Grelan Pharmaceutical Co., Ltd., Hamura | Darmlösliche sprudelnde zusammensetzungen |
| AU757139B2 (en) | 1998-10-20 | 2003-02-06 | University Of North Carolina At Chapel Hill, The | Methods of hydrating mucosal surfaces |
| US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| EP1187639A1 (en) | 1999-06-04 | 2002-03-20 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| HUP0300491A2 (en) * | 2000-02-28 | 2003-07-28 | Vectura Ltd | Improvements in or relating to the delivery of oral drugs |
| US6881731B1 (en) * | 2000-10-23 | 2005-04-19 | Shanbrom Technologies, Llc | Enhancers for microbiological disinfection |
| ATE305774T1 (de) * | 2001-02-27 | 2005-10-15 | Roehm Gmbh | Überzugs- und bindemittel für arzneimittelformulierungen mit verbesserter lagerstabilität |
| US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| EP1663235B1 (en) | 2003-08-18 | 2013-07-24 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| CA2538763C (en) * | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| RU2527893C2 (ru) * | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| WO2007084253A2 (en) * | 2005-11-28 | 2007-07-26 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| CN101107014B (zh) * | 2004-12-09 | 2011-01-26 | 拜尔动物保健有限责任公司 | 用酸稳定糖皮质激素酯 |
| RU2437679C2 (ru) * | 2004-12-09 | 2011-12-27 | Байер Энимэл Хельс ГмбХ | Стабилизация сложных эфиров глюкокортикоидов кислотами |
| DE102005055385A1 (de) * | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
| DK200500028A (da) * | 2005-01-07 | 2006-08-11 | Hansen Richard Brinch | Preparation for preventing or treating calcium deficiency conditions in mammals |
| EP1909834A2 (en) * | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| BRPI0818004B8 (pt) * | 2007-10-16 | 2021-05-25 | Biocon Ltd | composição farmacêutica sólida administrável por via oral e o processo da mesma. |
| MX344703B (es) | 2008-02-26 | 2017-01-03 | Parion Sciences Inc | Bloqueadores de canal de sodio poliaromaticos. |
| EP2723176B1 (en) | 2011-06-27 | 2017-04-12 | Parion Sciences, Inc. | A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| SI2931713T1 (sl) | 2012-12-17 | 2017-03-31 | Parion Sciences, Inc. | Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice |
| AU2013363215B2 (en) | 2012-12-17 | 2018-03-01 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3276959A (en) * | 1963-08-08 | 1966-10-04 | Hefa G M B H | Stabilized steroid compositions |
| JPS54158435A (en) * | 1978-06-05 | 1979-12-14 | Nippon Shikizai Kogyo Kenkyusho:Kk | Surface treatment |
| US4294952A (en) * | 1978-11-30 | 1981-10-13 | Hitachi Chemical Company, Ltd. | Polyamide-imide resin and its production |
| JPS6034925B2 (ja) * | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
| US4289764A (en) * | 1979-12-04 | 1981-09-15 | Drythanol Ltd. | Steroid compositions |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
-
1983
- 1983-08-01 JP JP58139466A patent/JPS6032714A/ja active Granted
-
1988
- 1988-02-04 US US07/153,527 patent/US4835142A/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008522997A (ja) * | 2004-12-09 | 2008-07-03 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 酸によるグルココルチコイドエステルの安定化 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0251528B2 (enExample) | 1990-11-07 |
| US4835142A (en) | 1989-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6032714A (ja) | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 | |
| CA2372231C (en) | Aerosol formulations and devices for increasing libido in women via acute testosterone administration | |
| AU2006256518B2 (en) | Method and composition for treating inflammatory disorders | |
| BR9710115B1 (pt) | composiÇço aquosa farmacÊutica, e processo de preparaÇço de uma composiÇço aquosa farmacÊutica. | |
| KR101052693B1 (ko) | 건조 분말 흡입용 조성물의 제조방법 | |
| JPS6034925B2 (ja) | 持続性鼻腔用製剤およびその製造法 | |
| JP3221880B2 (ja) | 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用 | |
| BG65350B1 (bg) | Стабилен концентрат на формотерол | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| KR102462058B1 (ko) | 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물 | |
| EP1137398B1 (en) | Pharmaceutical preparation for inhalation of an opioid | |
| CA2544422C (en) | Soft steroid compositions for use in dry powder inhalers | |
| JP2005132801A (ja) | 口腔内崩壊錠 | |
| JP2021506897A (ja) | フドステインのエアロゾル吸入用溶液製剤及びその製造方法 | |
| AU2007311607A1 (en) | Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate | |
| JP3386348B2 (ja) | 鼻腔内投与用水性懸濁製剤 | |
| WO2003068315A1 (en) | A pulmonary drug delivery composition containing a progestogen and an androgen for use in a contraceptive method in males | |
| CN112137957B (zh) | 一种药用吸入气雾剂及其制备方法 | |
| JP2008273899A (ja) | 経鼻吸収用睡眠導入剤 | |
| JP2005281315A6 (ja) | 水性薬理組成物 | |
| JP2005281315A (ja) | 水性薬理組成物 | |
| JP2004018491A (ja) | プロスタグランジン含有経鼻投与製剤組成物 | |
| TW201717936A (zh) | 噴霧器用組成物 | |
| CN103006570B (zh) | 一种阿佐昔芬速释微丸及其制备方法 | |
| MXPA06004984A (en) | Soft steroid compositions for use in dry powder inhalers |